WO1998024894A3 - Pkd1-fragmente mit bindungsregionen für pkd1-spezifische antikörper - Google Patents

Pkd1-fragmente mit bindungsregionen für pkd1-spezifische antikörper Download PDF

Info

Publication number
WO1998024894A3
WO1998024894A3 PCT/DE1997/002832 DE9702832W WO9824894A3 WO 1998024894 A3 WO1998024894 A3 WO 1998024894A3 DE 9702832 W DE9702832 W DE 9702832W WO 9824894 A3 WO9824894 A3 WO 9824894A3
Authority
WO
WIPO (PCT)
Prior art keywords
pkd1
fragments
specific antibodies
bonding areas
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1997/002832
Other languages
English (en)
French (fr)
Other versions
WO1998024894A2 (de
Inventor
Hanswalter Zentgraf
Iris Velhagen
Regina Martens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
German Cancer Research Center
Original Assignee
German Cancer Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by German Cancer Research Center filed Critical German Cancer Research Center
Publication of WO1998024894A2 publication Critical patent/WO1998024894A2/de
Publication of WO1998024894A3 publication Critical patent/WO1998024894A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Die vorliegende Erfindung betrifft PKD1-Fragmente mit Bindungsregionen für PKD1-spezifische Antikörper, solche Fragmente codierende DNA und ein Verfahren zur Herstellung solcher Fragmente. Ferner betrifft die Erfindung die Verwendung der Fragmente und der DNA sowie gegen die Fragmente gerichtete Antikörper.
PCT/DE1997/002832 1996-12-06 1997-12-03 Pkd1-fragmente mit bindungsregionen für pkd1-spezifische antikörper Ceased WO1998024894A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1996150758 DE19650758C1 (de) 1996-12-06 1996-12-06 PKD1-Fragmente mit Bindungsregionen für PKD1-spezifische Antikörper
DE19650758.8 1996-12-06

Publications (2)

Publication Number Publication Date
WO1998024894A2 WO1998024894A2 (de) 1998-06-11
WO1998024894A3 true WO1998024894A3 (de) 1998-07-16

Family

ID=7813903

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1997/002832 Ceased WO1998024894A2 (de) 1996-12-06 1997-12-03 Pkd1-fragmente mit bindungsregionen für pkd1-spezifische antikörper

Country Status (2)

Country Link
DE (1) DE19650758C1 (de)
WO (1) WO1998024894A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2550361B1 (de) * 2010-03-25 2017-02-08 The J. David Gladstone Institutes Zusammensetzungen und verfahren zur behandlung neurologischer störungen
WO2023056450A1 (en) * 2021-09-30 2023-04-06 Yale University Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034649A2 (en) * 1994-06-14 1995-12-21 Medical Research Council Polycystic kidney disease 1 gene and uses thereof
WO1995034573A1 (en) * 1994-06-03 1995-12-21 Brigham And Women's Hospital Identification of polycystic kidney disease gene, diagnostics and treatment
WO1996012033A1 (en) * 1994-10-12 1996-04-25 Genzyme Corporation Polycystic kidney disease gene
WO1997044457A1 (en) * 1996-05-24 1997-11-27 Genzyme Corporation Polycystic kidney disease gene

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034573A1 (en) * 1994-06-03 1995-12-21 Brigham And Women's Hospital Identification of polycystic kidney disease gene, diagnostics and treatment
WO1995034649A2 (en) * 1994-06-14 1995-12-21 Medical Research Council Polycystic kidney disease 1 gene and uses thereof
WO1996012033A1 (en) * 1994-10-12 1996-04-25 Genzyme Corporation Polycystic kidney disease gene
WO1997044457A1 (en) * 1996-05-24 1997-11-27 Genzyme Corporation Polycystic kidney disease gene

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BURN T C ET AL: "ANALYSIS OF THE GENOMIC SEQUENCE FOR THE AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (PKD1) GENE PREDICTS THE PRESENCE OF A LEUCINE-RICH REPEAT", HUMAN MOLECULAR GENETICS, vol. 4, no. 4, April 1995 (1995-04-01), pages 575 - 582, XP002043048 *
GLUECKSMANN-KUIS M A ET AL: "POLYCYSTIC KIDNEY DISEASE: THE COMPLETE STRUCTURE OF THE PKD1 GENE AND ITS PROTEIN", CELL, vol. 81, 21 April 1995 (1995-04-21), pages 289 - 298, XP002043049 *
HUGHES J ET AL: "THE POLYCYSTIC KIDNEY DISEASE 1 (PKD1) GENE ENCODES A NOVEL PROTEIN WITH MULTIPLE CELL RECOGNITION DOMAINS", NATURE GENETICS, vol. 10, 10 June 1995 (1995-06-10), pages 151 - 159, XP002044158 *
WARD C J ET AL: "THE POLYCYSTIC KIDNEY DISEASE 1 GENE ENCODES A 14 KB TRANSCRIPT AND LIES WITHIN A DUPLICATED REGION ON CHROMOSOME 16", CELL, vol. 77, 17 June 1994 (1994-06-17), pages 881 - 894, XP002044159 *

Also Published As

Publication number Publication date
DE19650758C1 (de) 1998-01-02
WO1998024894A2 (de) 1998-06-11

Similar Documents

Publication Publication Date Title
WO2000001815A3 (en) Neurotrophic factors
WO2001004144A3 (de) Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
WO1999025847A3 (en) Cellulase produced by actinomycetes and method of producing same
AU2455295A (en) Protein or polypeptide, process for producing the same, and intermediate compound tehrefor
WO1999025846A3 (en) Cellulase produced by actinomycetes and method for producing same
DE69534778D1 (en) Cathepsin-02-protease
MXPA99001239A (es) Proceso mejorado para la produccion de bebidas alcoholicas que utilizan semilla de malta.
WO2002072826A3 (en) Neurotrophic factors
WO1996027665A3 (en) Neuron-restrictive silencer factor proteins
EP0869174A3 (de) Verfahren zur Kolonierung und Herstellung von Spel Restriktionsendonuclease
WO2001042441A3 (en) Plastid transformation
WO2001019970A3 (en) Chymotrypsin-free trypsin
EP0861838A3 (de) Verfahren und Intermediate zur Herstellung von Cryptophycinverbindungen
AU5336398A (en) Method to produce multi-layer plates, the relative plant and multi-layer plates obtained therewith
WO1999010480A3 (de) Neue gewebsspezifische calpaine, ihre herstellung und verwendung
WO1997035015A3 (de) Tyrosin-phosphatase-verwandtes protein
EP0931835A3 (de) Verfahren zur Klonierung und Herstellung von Restriktionsendonuklease PmeI
WO1999002659A3 (en) Method of altering the domains of cyclosporin synthetase to give a modified cyclosporin synthetase
WO1999001475A3 (de) Humaner antikörper gegen ein fusions(poly)peptid bzw. -protein, das einen anteil von mindestens sechs histidinen aufweist
WO1999053091A3 (de) Gdnf-kodierende dna, teile davon und gdnf-varianten
AU7676698A (en) Method for the production of a branched macromolecule, the branched macromolecule and uses thereof
WO1998044103A3 (de) Protein zur inhibierung von apoptose
WO2000031254A3 (en) Apoptosis-inducing factor
WO1997016457A3 (de) Protein mit anti-tumorwirkung
WO1998030687A3 (de) Srcr domäne-enthaltendes protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase